Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results No significant financial relationships to disclose. This ...
Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation. This is an ASCO Meeting Abstract from the 2019 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback